8-KMaterial AgreementsFinancial Events

DEXCOM INC 8-K Report, Material Agreement (Oct 14, 2021)

Filed October 14, 2021For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has entered into a Second Amended and Restated Credit Agreement, significantly enhancing its financial flexibility. This new agreement provides a $200.0 million revolving credit facility, with an option to increase it by up to an additional $300.0 million, potentially bringing the total available to $500.0 million. The facility is available for general corporate purposes, including working capital and capital expenditures, and allows for borrowings in multiple currencies. This strategic move indicates DexCom's proactive approach to managing its capital structure and supporting future growth initiatives. The company had no outstanding loans under the previous agreement, highlighting its strong liquidity position. The Amended Credit Agreement also includes customary covenants and events of default, with a maturity date of October 13, 2026, ensuring a stable financing runway.

Key Highlights

  • 1DexCom entered into a Second Amended and Restated Credit Agreement, establishing a $200.0 million revolving credit facility.
  • 2The company has the option to increase the credit facility by an additional $300.0 million, potentially reaching a total of $500.0 million.
  • 3Funds from the revolving credit facility are designated for general corporate purposes, including working capital and capital expenditures.
  • 4The agreement allows for borrowings in USD and includes a $50.0 million sublimit for borrowings in various foreign currencies.
  • 5As of the filing date, DexCom had no outstanding loans under the previous credit agreement, indicating a strong current liquidity position.
  • 6The credit agreement matures on October 13, 2026, providing a five-year financing term.
  • 7The obligations are secured by substantially all of DexCom's assets and are guaranteed by future wholly-owned domestic material subsidiaries.

Frequently Asked Questions

The Second Amended and Restated Credit Agreement provides DexCom with enhanced financial flexibility, offering a $200.0 million revolving credit facility (with an option to increase up to $500.0 million) for general corporate purposes, including working capital and capital expenditures, and supporting potential future growth.

No, as of October 13, 2021, DexCom had no outstanding loans under the existing credit agreement, indicating a strong liquidity position prior to entering into the new agreement.

The Amended Credit Agreement matures on October 13, 2026, which is five years from the effective date of the agreement.

DexCom can borrow in US Dollars and has a $50.0 million sublimit for borrowings in Canadian Dollars, Euros, British Pounds, Swedish Kroner, Japanese Yen, Australian Dollars, New Zealand Dollars, and other approved currencies.